Consumer goods and pharma major GSK plc (GSK) on Thursday confirmed that it has reached a confidential settlement with Boyd/Steenvoord resolving the case that was filed in the California state court.
The trial that was set to begin on April 2 will be dismissed.
Zantac (ranitidine) is a drug for heartburn that has been removed from the markets over allegations that it causes cancer.
"The settlements reflect the Company's desire to avoid the distraction related to protracted litigation. GSK does not admit any liability in the settlements and will continue to vigorously defend itself based on the facts and the science in all other Zantac cases," the company said in a statement.
On Wednesday, GSK shares closed at 1,669.80 pence, down 0.07% in London.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.